TScan Therapeutics, Inc. (TCRX) › Shareholders' EquityTScan Therapeutics, Inc. (TCRX) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$17.14M2020: -$42.46M2021: $160.78M2022: $99.43M2023: $150.87M2024: $240.97M2025: $123.12M$123.12M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$123.12M-48.9%2024$240.97M+59.7%2023$150.87M+51.7%2022$99.43M-38.2%2021$160.78M+478.6%2020-$42.46M-147.8%2019-$17.14M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share